It has been described as an attractive therapeutic target to prevent viral infections, as SLC35B2 knockout did not affect the viability of normal cells, but prevented viral infection due to decreased sulfation of proteins or proteoglycans essential for viral entry [38–40]. This evidence concerns the gene SLC35B2 and viral infectious disease.